Eikon Therapeutics, a company focused on the application of superresolution microscopy to drug discovery, closed a $517.8 million Series B financing round. Since its founding, Eikon Therapeutics has raised more than $688 million. The company has also completed recruitment of its leadership team. The company has now named Daniel Anderson as chief scientific officer, Russ Berman as chief technical officer, Alfred Bowie Jr. as CFO, Barbara Howes as chief people officer, Ashish Kheterpal as chief information officer, and Ben Thorner as general counsel and chief business officer.
